AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes
A Pair Of ‘Wild Card’ Studies Pay Off
Executive Summary
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
You may also be interested in...
Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’
Sanofi's SERD Candidate Founders In Advanced Breast Cancer
The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.
Menarini And Radius Skip Into SERD Lead With Elacestrant Success
Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.